ADME & Pharmacokinetics

What Is ADME?

ADME stands for Absorption, Distribution, Metabolism, and Excretion — the four fundamental processes that determine how a drug moves through the body. Together, these processes define a compound's pharmacokinetic (PK) profile and play a central role in determining whether a drug candidate will be safe and effective in humans.

Understanding ADME properties early in drug development is critical. Poor pharmacokinetics and bioavailability were historically responsible for a significant portion of clinical failures. Today, ADME screening has moved earlier in the drug discovery pipeline, helping teams identify and address liabilities before committing to costly in vivo studies and clinical trials.

The Four ADME Components

Pharmacokinetic Fundamentals

Pharmacokinetics is often summarized as "what the body does to the drug" — in contrast to pharmacodynamics, which is "what the drug does to the body." PK studies quantify the time course of drug concentration in blood, plasma, tissues, and excreta following administration.

PK data are essential for establishing dose-exposure relationships, predicting human doses from animal data, and designing safe and effective dosing regimens. In preclinical development, PK studies help bridge in vitro findings to in vivo performance and support the transition from animal models to first-in-human trials.

Compartmental vs. Non-Compartmental Analysis

PK data are typically analyzed using either compartmental models (which describe the body as one or more interconnected compartments with defined rate constants) or non-compartmental analysis (NCA), which calculates PK parameters directly from the concentration-time data without assuming a specific model. NCA is the more common approach in preclinical studies due to its simplicity and regulatory acceptance.

Key PK Parameters

Understanding PK parameters is essential for interpreting study results and making informed decisions about compound progression.

In Vitro ADME Studies

In vitro ADME assays are the first line of characterization for drug candidates, typically performed during lead optimization before committing to animal studies. These assays are rapid, cost-effective, and generate data used to rank-order compounds and predict in vivo behavior.

Core In Vitro Assays

• Metabolic Stability: Incubation with liver microsomes or hepatocytes to determine intrinsic clearance and predict in vivo half-life. Microsomes assess Phase I metabolism (CYP-mediated), while hepatocytes capture both Phase I and Phase II (conjugation) pathways.
• CYP Inhibition & Induction: Screening against major CYP isoforms (1A2, 2C9, 2C19, 2D6, 3A4) to identify potential drug-drug interaction (DDI) liabilities. These assays are required by FDA guidance.
• Permeability (Caco-2 / MDCK): Cell-based assays to predict intestinal absorption and evaluate P-glycoprotein (P-gp) efflux. Low permeability or high efflux can significantly limit oral bioavailability.
• Plasma Protein Binding: Determination of the fraction of drug bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein). Only unbound drug is pharmacologically active and available for distribution and elimination.
• Plasma Stability: Assessment of chemical and enzymatic stability in plasma, particularly important for peptide, prodrug, and ester-containing compounds.
• Metabolite Identification: Using liver microsomes, hepatocytes, or recombinant enzymes with LC-MS/MS to identify major metabolic pathways and metabolites that may require further toxicological evaluation.

In Vivo PK Studies

In vivo pharmacokinetic studies in animal models are essential for understanding systemic exposure, validating in vitro predictions, and generating data for human dose projection. These studies typically progress from rodents (mice, rats) through non-rodents (dogs, nonhuman primates) as development advances.

Single-Dose PK Studies

The most common initial in vivo PK study involves administering a single dose (IV and/or the intended clinical route) to animals and collecting serial blood samples over time. IV dosing provides absolute bioavailability data, while extravascular dosing (oral, subcutaneous, etc.) characterizes absorption and first-pass effects.

Repeat-Dose PK / Toxicokinetics

In GLP toxicology studies, toxicokinetic (TK) assessments are incorporated to measure systemic exposure at steady state. TK data from these studies are critical for establishing exposure margins between animal NOAEL doses and projected human doses, directly supporting IND submissions.

Special PK Studies

• Tissue Distribution: Quantitative whole-body autoradiography (QWBA) or tissue collection studies to map drug distribution across organs. Particularly important for CNS-targeted drugs (to confirm brain penetration) and oncology compounds.
• Mass Balance / Excretion: Radiolabeled (¹⁴C) studies in animals to determine the routes and extent of elimination. Required by regulators to fully characterize the disposition of a drug candidate.
• Food Effect Studies: Assessment of how food intake alters oral absorption and exposure — important for defining clinical dosing instructions.
• Dose Proportionality: Multi-dose level studies to evaluate whether exposure increases linearly with dose, or whether saturation of absorption, metabolism, or clearance mechanisms results in non-linear kinetics.

Species Considerations for PK Studies

The choice of animal species for PK studies has a significant impact on the translatability of results to humans. Key factors include metabolic enzyme homology, physiological similarity, and practical considerations such as blood volume and sampling frequency.

Bioanalytical Methods

Reliable PK data depend on validated bioanalytical methods for quantifying drug concentrations in biological matrices. The bioanalytical component of ADME/PK work is often the rate-limiting step and deserves careful attention in CRO selection.

Common Platforms

• LC-MS/MS: The gold standard for small molecule quantification. Offers high sensitivity, selectivity, and throughput. Method development and validation according to FDA/EMA bioanalytical guidance is essential for GLP studies.
• Ligand-Binding Assays (ELISA, MSD): Used for large molecules (biologics, antibodies, peptides). These immunoassays can distinguish total drug from free drug and may also detect anti-drug antibodies (ADA).
• HPLC-UV/Fluorescence: Simpler detection methods used when analyte concentrations are sufficiently high and matrix interference is manageable.

Method Validation Essentials

For GLP-regulated studies, bioanalytical methods must be validated for accuracy, precision, selectivity, sensitivity (LLOQ), linearity, matrix effects, and stability. The validation must follow current FDA or EMA guidance documents, and the validated method range must cover expected study concentrations.

Regulatory Context

ADME and PK data are integral to every major regulatory submission in drug development.

IND Application

The IND submission must include single-dose and repeat-dose PK data in at least two species, bioavailability data for the intended clinical route, and toxicokinetic data from GLP toxicology studies. In vitro metabolism and DDI data (CYP inhibition/induction) are also expected.

Key Regulatory Guidances

• FDA: Guidance for Industry — Safety Testing of Drug Metabolites (MIST guidance); In Vitro Drug Interaction Studies; Bioanalytical Method Validation
• ICH M3(R2): Nonclinical Safety Studies for the Conduct of Human Clinical Trials — defines the timing and scope of ADME studies relative to clinical development
• ICH S3A/S3B: Guidances on toxicokinetics and pharmacokinetics to support clinical studies

Choosing a CRO for ADME/PK Studies

Selecting the right CRO partner for ADME and pharmacokinetic work is critical. Consider the following when evaluating potential partners:

• Integrated Capabilities: CROs that offer both in vitro ADME screening and in vivo PK studies under one roof can provide faster turnaround and better data integration. Look for organizations that also have in-house bioanalytical capabilities.
• Bioanalytical Expertise: The quality of PK data is only as good as the bioanalytical method behind it. Evaluate the CRO's LC-MS/MS and ligand-binding assay capabilities, instrument fleet, and experience with GLP method validation.
• Species Availability: Confirm that the CRO has the animal species you need, along with appropriate housing, dosing capabilities, and serial sampling infrastructure. For NHP studies, this is particularly important given limited availability.
• PK Scientists & Data Analysis: Experienced pharmacokineticists who can design studies, perform NCA or compartmental modeling, and interpret results in the context of your program are invaluable. Ask about the team's experience with allometric scaling and human dose projection.
• Regulatory Track Record: For GLP studies and IND-enabling work, verify that the CRO has a strong quality assurance program and a history of regulatory inspections without critical findings.